Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
Toronto General Hospital, University Health Network
Toronto, Ontario, Canada
RECRUITINGPost-transplant anti-A antibody titers
Time frame: post-op day 5 or day 12
Primary graft dysfunction grade
Time frame: post-op day 0, 1, 2, 3
Incidence of hyperacute antibody-mediated rejection
Time frame: post-op day 1, 2
C4d positivity on transbronchial biopsy samples
Time frame: 1 year
Incidence and severity of acute cellular rejection
Time frame: 1 year
Bleeding
Time frame: post-op day 1-7
Infection
Time frame: 10 years
Graft function
Time frame: 10 years
Incidence of malignancy
Time frame: 10 years
Chronic lung allograft dysfunction
Time frame: 10 years
Time to death or re-transplantation
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.